Kronos Bio IPO. Gilead’s SYK Inhibitor Portfolio Will Boost The Pipeline
A clinical-stage biotech company Kronos Bio, founded by partners and executives from Two River Group, priced its IPO of ~13.1 million shares at...
503 Views
Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3.4/5
Kronos Bio (KRON US)
Kronos Bio (KRON US)
14
Analysis
Health Care • United States
Kronos Bio, Inc. operates as a biotechnology company. The Company discovers and develops therapies that modulate historically recalcitrant cancer targets. Kronos Bio serves customers in worldwide.
morex